10x Genomics offers an end‑to‑end platform for high‑throughput single‑cell and spatial genomics, combining Chromium X instruments, Flex Apex multiplexing, and universal 3′/5′ chemistries to profile gene expression, protein markers, and other molecular features from diverse sample types. Integrated software tools such as Cell Ranger, cloud‑based analysis, and the Loupe Browser automate data processing and visualization, enabling researchers to scale from pilot studies to large projects with high sensitivity and reproducibility.

Abdera is developing targeted alpha therapies (TATs) using its ROVEr™ platform, which combines antibody engineering with radiopharmaceuticals to deliver radionuclide payloads directly to solid tumors. The company aims to improve treatment outcomes for patients with relapsed, refractory, and metastatic cancers while minimizing systemic toxicities.

Aclaris Therapeutics leverages its KINect® platform to discover covalent kinase inhibitors and dual‑targeting bispecific antibodies that modulate key inflammatory signaling pathways. It advances oral, topical, and biologic candidates for immuno‑inflammatory conditions such as atopic dermatitis, asthma, COPD, and inflammatory bowel disease, and provides licensing and co‑development partnerships to pharmaceutical and biotechnology companies.

Adapt is a social learning platform that combines educational systems with community engagement to create accessible learning environments. The platform aims to expand educational opportunities in underserved communities, fostering collaboration and knowledge sharing among users.

Adaptive provides an agentless privileged access management control plane for hybrid environments, securing human, workload, and AI identities. The platform enables just-in-time access to resources like databases, VMs, and cloud infrastructure without sharing credentials. It also offers database activity monitoring and data protection through masking and tokenization to enforce least privilege.

Adicet Bio develops allogeneic gamma delta CAR T cell therapies to target and eliminate cancer cells, utilizing the unique properties of gamma delta T cells for enhanced tissue homing and drug exposure. This approach addresses the need for effective, on-demand immunotherapies in the treatment of cancer and autoimmune diseases.

Aetion offers a cloud‑native platform that ingests heterogeneous health data (EHR, claims, registries) and provides guardrailed ETL pipelines, validated causal‑inference analytics, and AI‑driven synthetic data generation to produce regulatory‑ready real‑world evidence. Its visual dashboards, APIs, and compliance controls enable biopharma, med‑tech firms, and regulators to generate reproducible evidence in weeks rather than months.

Akero Therapeutics is developing Efruxifermin (EFX), a therapeutic agent aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) by restoring metabolic balance in patients. The company conducts clinical trials to evaluate the efficacy of EFX in reversing the progression of this serious liver disease.

Alecto builds advanced digital platforms to strengthen organizational cybersecurity and privacy. Their solutions address complex threat landscapes for government and enterprise clients, enhancing digital defenses and resilience.

Alumis develops oral therapies using a precision medicine approach to target immune-mediated diseases, focusing on the underlying drivers of immune dysfunction through genetic and translational insights. The company aims to improve clinical outcomes for patients suffering from autoimmune disorders by optimizing therapeutic interventions.

ALX Oncology is developing evorpacept, a high-affinity CD47 blocking fusion protein designed to enhance immune system recognition of cancer cells while minimizing hematologic toxicities. This approach targets the "don't eat me" signal used by cancer cells, aiming to improve therapeutic outcomes in combination with existing anti-cancer agents.

Arcus Biosciences develops combination therapies using differentiated small molecules and antibodies to enhance treatment efficacy for various cancers. The company focuses on optimizing biologic mechanisms to improve patient outcomes and accelerate the delivery of new cancer therapies through global clinical trials.

ARS Pharmaceuticals develops neffy, the first FDA-approved needle-free epinephrine nasal spray, providing a portable and easy-to-use alternative for individuals at risk of severe allergic reactions. This product addresses the challenges of needle-related risks and the anxiety associated with traditional epinephrine delivery methods.

Bio provides a digital health management platform that integrates 24/7 telemedicine services with personalized care coordination, utilizing data intelligence to enhance patient engagement and streamline healthcare delivery. The platform addresses the challenges of accessibility and continuity in healthcare by offering tailored support for chronic conditions and immediate medical assistance through a user-friendly web application.

Den is a multisig wallet solution that enables onchain teams to execute secure transactions quickly, allowing users to send both crypto and fiat, swap tokens, and interact with decentralized applications. By automating signer coordination and transaction simulations, Den eliminates the inefficiencies of manual approvals and enhances transaction safety, having facilitated over $1 billion in transactions for more than 400 teams.

Duro offers a cloud-based Product Lifecycle Management (PLM) platform that centralizes part data and manages change orders, ensuring data continuity across design and manufacturing processes. This integration reduces miscommunication between engineering and manufacturing teams, leading to lower development costs and improved accuracy in production.

Evonetix is developing a desktop platform that synthesizes gene-length DNA with high accuracy and scalability using a novel approach to DNA synthesis. This technology provides researchers with rapid access to precise genetic material, addressing the limitations of current gene synthesis methods that hinder innovation in healthcare and biotechnology.

Fin provides zero-emission parcel delivery and logistics services using an all-electric fleet of vans and e-cargo bikes, optimizing urban logistics through city center micro-fulfilment hubs. This approach reduces delivery costs and eliminates carbon emissions associated with last-mile logistics for e-commerce brands.

Foresight Diagnostics utilizes PhasED-Seq™ technology to detect circulating tumor DNA (ctDNA) from a simple blood draw, enabling the identification of minimal residual disease (MRD) across various cancer types. This ultra-sensitive platform provides actionable insights throughout the patient treatment journey, enhancing cancer drug development and patient care.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

IMMUSE Therapeutics develops immune-based therapies that target both tumor cells and immune cells within the tumor microenvironment, enhancing the efficacy of cancer treatment. This dual-targeting approach aims to increase tumor cell toxicity while boosting the activity of immune cells, improving patient outcomes in immune-related diseases.

Interline Therapeutics is a drug discovery platform that utilizes advanced mapping techniques to identify and rectify dysfunctional protein communities. This approach addresses the challenges of protein misfolding and aggregation, which are implicated in various diseases, by restoring normal protein function.

Latigo is a clinical-stage company developing non-opioid pain medications that target pain at its source, aiming to provide effective and rapid relief without the risk of addiction. The company addresses the significant unmet need for new pain therapies, as current treatments often lead to dependency and have remained unchanged for decades.

Provides a shared progress tracking platform for coaches and clients, enabling clients to log actions, track goals, and maintain accountability between sessions. Coaches gain measurable insights into client progress and engagement through customizable logs, reminders, and real-time feedback tools, improving the effectiveness of their practice.